AI Article Synopsis
- T-VEC is an intralesional treatment for advanced melanoma that has been studied alongside anti-PD-1 therapies in real-world scenarios.
- A review of T-VEC use from January 2017 to March 2018 included 83 melanoma patients, revealing three usage patterns: only T-VEC, T-VEC after anti-PD-1, and T-VEC concurrent with anti-PD-1.
- A quarter of patients stopped T-VEC due to the absence of injectable lesions, while 37% stopped due to disease progression, showing no significant differences based on the timing or presence of anti-PD-1 therapy.
Article Abstract
Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma. T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization.
Materials & Methods: A retrospective review of T-VEC use from 1 January 2017 and 31 March 2018 for melanoma patients was conducted at seven US institutions.
Results: Among 83 patients, three categories of T-VEC and anti-PD-1 therapy were identified: T-VEC used without anti-PD-1 (n = 29, 35%), T-VEC after anti-PD-1-based therapy (n = 22, 27%) and concurrent T-VEC and anti-PD-1-based therapy (n = 32, 39%). 25% of patients discontinued T-VEC therapy due to no remaining injectable lesions, 37% discontinued T-VEC due to progressive disease. Discontinuation of T-VEC did not differ by anti-PD-1-based therapy use or timing.
Conclusion: In real-world settings, T-VEC may be used concurrently with or after anti-PD-1-based therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426742 | PMC |
| http://dx.doi.org/10.2217/mmt-2020-0005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!